High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

ClinicalTrials.gov ID: NCT00536601

Public ClinicalTrials.gov record NCT00536601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with hematologic cancer or solid tumors. Giving high-dose chemotherapy with or without TBI before ASCT stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood or bone marrow and stored. More chemotherapy may be given to prepare for the stem cell transplant. The stem cells are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy.

Study identification

NCT ID: NCT00536601
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: 174 participants

Conditions and interventions

Conditions

Interventions

etoposide Drug
cyclophosphamide Drug
carmustine Drug
melphalan Drug
busulfan Drug
carboplatin Drug
thiotepa Drug
total-body irradiation Radiation
autologous hematopoietic stem cell transplantation Procedure
autologous-autologous tandem hematopoietic stem cell transplantation Procedure

Drug · Radiation · Procedure

Eligibility (public fields only)

Age range: 4 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 28, 2006
Primary completion: Jul 8, 2018
Completion: Jul 8, 2018
Last update posted: Apr 21, 2021

2006 – 2018

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00536601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2021 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00536601 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →